Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346


Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.


Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.


Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis.

Ghiassi-Nejad Z, Ru M, Moshier E, Chang S, Jagannath S, Dharmarajan K.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):310-319. doi: 10.1016/j.clml.2019.01.004. Epub 2019 Jan 19.


Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.

Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00019. Epub 2018 Aug 8.


Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies.

Richter J, Jagannath S.

Cancer J. 2019 Jan/Feb;25(1):32-37. doi: 10.1097/PPO.0000000000000351.


Understanding Paper-Based Documentation Practices in Medical Resuscitations to Inform the Design of Electronic Documentation Tools.

Jagannath S, Sarcevic A, Multak N, Myers S.

Pediatr Emerg Care. 2018 Dec 21. doi: 10.1097/PEC.0000000000001676. [Epub ahead of print]


Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.

Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richter J, Chari A.

Front Immunol. 2018 Nov 15;9:2616. doi: 10.3389/fimmu.2018.02616. eCollection 2018. Review.


Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.


A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.


An Analysis of Speech as a Modality for Activity Recognition during Complex Medical Teamwork.

Jagannath S, Sarcevic A, Marsic I.

Int Conf Pervasive Comput Technol Healthc. 2018 May;2018:88-97. doi: 10.1145/3240925.3240941.


Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma.

Richter J, Jagannath S.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):693-702. doi: 10.1016/j.clml.2018.09.003. Epub 2018 Sep 20. Review.


Recurrent Acute Pancreatitis: Current Concepts in the Diagnosis and Management.

Jagannath S, Garg PK.

Curr Treat Options Gastroenterol. 2018 Dec;16(4):449-465. doi: 10.1007/s11938-018-0196-9. Review.


BK virus characterisation among HIV-1-Infected individuals and its association with immunosuppression.

Jagannath S, Sachithanandham J, Ramalingam VV, Demosthenes JP, Abraham AM, Zachariah A, Varghese GM, Kannangai R.

Indian J Med Microbiol. 2018 Apr-Jun;36(2):172-177. doi: 10.4103/ijmm.IJMM_18_54.


Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Abonour R, Wagner L, Durie BGM, Jagannath S, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Kitali A, Gibson CJ, Srinivasan S, Swern AS, Rifkin RM.

Ann Hematol. 2018 Dec;97(12):2425-2436. doi: 10.1007/s00277-018-3446-y. Epub 2018 Jul 29.


Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

Rifkin RM, Jagannath S, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Parikh K, Abouzaid S, Srinivasan S, Kitali A, Zafar F, Abonour R.

Clin Ther. 2018 Jul;40(7):1193-1202.e1. doi: 10.1016/j.clinthera.2018.05.017. Epub 2018 Jul 23. Review.


Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.

Jagannath S, Abonour R, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Wagner L, Agarwal A, Srinivasan S, Kitali A, Flick ED, Sturniolo M, Rifkin RM.

Blood Adv. 2018 Jul 10;2(13):1608-1615. doi: 10.1182/bloodadvances.2018017186.


Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A.

Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998. Erratum in: Blood Adv. 2018 Sep 11;2(17):2186.


Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).

Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, Terebelo HR, Toomey K, Wagner L, Srinivasan S, Kitali A, Yue L, Flick ED, Agarwal A, Rifkin RM.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):480-485.e3. doi: 10.1016/j.clml.2018.04.007. Epub 2018 May 4.


Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.

Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.


Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R.

Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.


Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.


Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA.

J Clin Oncol. 2018 Mar 10;36(8):812-818. doi: 10.1200/JCO.2017.76.6402. Epub 2018 Jan 17.


A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S.

Blood Adv. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. eCollection 2017 Aug 22.


The effect of novel therapies in high-molecular-risk multiple myeloma.

Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A.

Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Review.


Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.

Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):44-51. doi: 10.1016/j.clml.2017.09.002. Epub 2017 Sep 19.


Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.

Tremblay D, Lancman G, Moshier E, Bar N, Jagannath S, Chari A.

Bone Marrow Transplant. 2017 Oct;52(10):1468-1470. doi: 10.1038/bmt.2017.160. Epub 2017 Jul 24. No abstract available.


Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):555-562. doi: 10.1016/j.clml.2017.06.020. Epub 2017 Jul 4.


Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Laganà A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, Kuo PY, Keats J, DeRome M, Yesil J, Auclair D, Lonial S, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.

Leukemia. 2018 Jan;32(1):120-130. doi: 10.1038/leu.2017.197. Epub 2017 Jun 23.


Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.


Novel and Experimental Therapies in Chronic Pancreatitis.

Jagannath S, Garg PK.

Dig Dis Sci. 2017 Jul;62(7):1751-1761. doi: 10.1007/s10620-017-4604-0. Epub 2017 May 27. Review.


Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.

Yanamandra U, Khattry N, Kumar S, Raje N, Jain A, Jagannath S, Menon H, Kumar L, Varma N, Varma S, Saikia T, Malhotra P; for IMAGe Group.

Indian J Hematol Blood Transfus. 2017 Mar;33(1):15-21. doi: 10.1007/s12288-016-0773-9. Epub 2017 Jan 2. Review.


Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.

Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S.

Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. doi: 10.1158/1078-0432.CCR-16-2526. Epub 2017 Jan 4.


The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.


Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J.

J Clin Pharmacol. 2017 May;57(5):663-677. doi: 10.1002/jcph.850. Epub 2016 Dec 7.


A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma.

Chari A, Mazumder A, Lau K, Catamero D, Galitzeck Z, Jagannath S.

Br J Haematol. 2018 Jan;180(2):296-298. doi: 10.1111/bjh.14314. Epub 2016 Oct 7. No abstract available.


International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.


Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.

Bloudek L, Roy A, Kish JK, Siegel DS, Jagannath S, Globe D, Orloski L, Kuriakose ET.

J Manag Care Spec Pharm. 2016 Aug;22(8):991-1002. doi: 10.18553/jmcp.2016.22.8.991.


Strategies for reducing police arrest in the context of an HIV prevention programme for female sex workers: evidence from structural interventions in Karnataka, South India.

Bhattacharjee P, Isac S, McClarty LM, Mohan HL, Maddur S, Jagannath SB, Venkataramaiah BK, Moses S, Blanchard JF, Gurnani V.

J Int AIDS Soc. 2016 Jul 18;19(4 Suppl 3):20856. doi: 10.7448/IAS.19.4.20856. eCollection 2016.


Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.

Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D.

Expert Rev Hematol. 2016 Jul;9(7):707-17. doi: 10.1080/17474086.2016.1195254. Epub 2016 Jun 16.


Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.

Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A.

Leuk Lymphoma. 2016 Dec;57(12):2833-2838. Epub 2016 Jun 7.


Advances in Management of Hepatocellular Carcinoma.

Jagannath S, Shalimar.

J Clin Exp Hepatol. 2016 Mar;6(1):68-70. doi: 10.1016/j.jceh.2016.03.006. Epub 2016 May 4. No abstract available.


Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.


VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):329-334.e1. doi: 10.1016/j.clml.2016.02.042. Epub 2016 Mar 4.


Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.

Barley K, He W, Agarwal S, Jagannath S, Chari A.

Leuk Lymphoma. 2016 Nov;57(11):2510-5. doi: 10.3109/10428194.2016.1151507. Epub 2016 Mar 4.


Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.


A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):711-9. doi: 10.1002/psp4.12044. Epub 2015 Nov 20.


Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S.

Cancer Res. 2016 Mar 1;76(5):1225-36. doi: 10.1158/0008-5472.CAN-15-2934. Epub 2016 Feb 12.


The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.

Bonomo L, Lue J, Jagannath S, Chari A.

Cancer Med. 2016 Mar;5(3):500-5. doi: 10.1002/cam4.620. Epub 2016 Jan 22.


Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt E, Paliwal P, Vij R.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38. doi: 10.1016/j.clml.2015.12.007. Epub 2015 Dec 21.

Supplemental Content

Loading ...
Support Center